Indivior PLC announces AGM details, addresses remuneration policy

Indivior PLC (LON:INDV) (NASDAQ:INDV), a pharmaceutical company specializing in the treatment of addiction, today disclosed upcoming corporate activities and shareholder communications in a recent SEC filing. The company, headquartered in North Chesterfield, VA, with a market capitalization of $1.2 billion and impressive gross profit margins of 82%, has published the notice for its 2025 Annual General Meeting (AGM) on its website and has sent out letters to its major institutional shareholders regarding the meeting’s agenda, particularly focusing on the remuneration policy. According to InvestingPro analysis, the company appears undervalued at its current trading price of $9.79.

The AGM Notice, available on Indivior’s official website, details the time, date, and items to be discussed during the meeting. Key among the agenda items is the company’s remuneration policy, which is a significant point of interest for shareholders, especially given management’s aggressive share buyback program. In an effort to provide clarity and context on this matter, Indivior dispatched a letter from the Chair of the Board and a joint letter from the current and incoming Chairs of the Compensation Committee. These letters aim to inform shareholders about the policy’s intricacies and the rationale behind it, ahead of the voting process at the AGM. InvestingPro subscribers can access detailed analysis of management effectiveness and compensation metrics in the comprehensive Pro Research Report, one of 1,400+ available company deep-dives.

The SEC filing, dated today, ensures that the information provided in the letters and the AGM Notice is not to be considered filed under the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section. It also states that the forward-looking statements included in the report, such as expectations regarding company performance and stock price, are subject to various risks and uncertainties. Notably, while analysts expect the company to return to profitability this year with projected earnings of $1.15 per share, three analysts have recently revised their earnings expectations downward for the upcoming period.

The company has emphasized that the forward-looking statements made in the report reflect only the company’s position as of the date of the report and that it does not commit to updating these statements in the future unless required by law. This cautionary note underscores the inherent uncertainty of business forecasts.

The announcement concludes with the inclusion of the AGM Notice as Exhibit 99.1 in the SEC filing, along with the letters to shareholders as Exhibits 99.2 and 99.3. The information is based on a press release statement and is intended to keep shareholders and the public informed of the latest corporate developments at Indivior PLC.

In other recent news, Indivior PLC announced its fourth-quarter 2024 earnings, reporting an earnings per share (EPS) of $0.32, which exceeded analyst projections of $0.26. The company also surpassed revenue expectations, achieving $298 million in net revenue against a forecast of $261.33 million. Despite these positive results, Indivior’s stock experienced a decline, reflecting investor concerns over future guidance and market conditions. The company’s flagship product, SUBLOCADE, saw a 20% increase in net revenue, contributing to a 2% year-over-year rise in overall net revenue for the quarter. For the full year 2024, Indivior reported a 9% increase in net revenue, with an adjusted operating profit of $312 million, marking a 16% growth. Looking ahead, Indivior projects 2025 as a transition year, with anticipated total net revenue between $955 million and $1,025 million. Additionally, Indivior announced upcoming changes to its Board of Directors, with the board set to be reduced to seven members, and a new Independent (LON:IOG) Non-Executive Director expected to be appointed by July 1, 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.